BioXcel Therapeutics Announces Proposed Public Offering
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing…
Pharmaceuticals, Biotechnology and Life Sciences
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing…
WOODRIDGE, Ill., Nov. 21, 2024 (GLOBE NEWSWIRE) — High Haven Dispensary, recognized as Illinois’ top-rated cannabis retailer, invites cannabis enthusiasts…
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) — BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing…
Conference Call to be held on December 3, 2024WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-…
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and…
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across…
– Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of…
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on…
Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months…